covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Enfermedad tromboembólica y anticonceptivos de tercera generación
Journal Information
Vol. 47. Issue 1.
Pages 36-39 (January 2004)
Share
Share
Download PDF
More article options
Vol. 47. Issue 1.
Pages 36-39 (January 2004)
Full text access
Enfermedad tromboembólica y anticonceptivos de tercera generación
Thromboembolic disease and third-generation oral contraceptives
Visits
4374
B. Cobo
Corresponding author
bcobo@piushospital.org

Correspondencia: Sant Fransec, s/n. 43800 Valls. Tarragona. España
, R. Armengol, P.A. Clemente
Servicio de Ginecología y Obstetricia, Pius. Hospital de Valls. Tarragona. España
This item has received
Article information
Resumen

La tromboembolia pulmonar es un proceso infrecuente. Presentamos un caso de tromboembolia pulmonar en una paciente joven, que se asocia al tratamiento con contraceptivos orales de tercera generación. Aunque la tromboembolia pulmonar es un trastorno infrecuente, en vista de la gravedad del proceso sería importante tenerla en cuenta antes de iniciar este tipo de tratamiento en pacientes jóvenes.

Se lleva a cabo, asimismo, una revisión de los diferentes artículos publicados sobre riesgo tromboembólico y el uso de anticonceptivos de tercera generación.

Palabras clave:
Trombosis venosa
Riesgo tromboembólico
Anticonceptivos orales
Abstract

Pulmonary thromboembolic disease (PTD) is rare. We report the case of a young woman who presented PTD associated with third-generation oral contraceptives. Although PTD is infrequent, due to its seriousness, it should be taken into account before prescribing this kind of treatment to young patients.

We also provide a review of the literature on thromboembolic risk and third-generation oral contraceptives.

Key words:
Venous thrombosis
Thromboembolic risk
Oral contraceptives
Full text is only aviable in PDF
Bibliografía
[1.]
A.V. Sapp, Lindbloom E.J..
Do third-generation oral contraceptives (OCs) increase the risk of venous thrombosis?.
J Fam Pract, 50 (2001), pp. 893
[2.]
J. Rosing, J. Curvers, G. Tans.
Oral contraceptives, thrombosis and haemostasis.
Eur J Obstet Gynecol Reprod Biol, 95 (2001), pp. 193-197
[3.]
F.R. Rosendaal, F.M. Helmerhorst, J.P. Vandenbroucke.
Oral contraceptives hormone replacement therapy and thrombosis.
Thromb Haemost, 86 (2001), pp. 112-123
[4.]
W.O. Spitzer, M.A. Lewis, L.A. Heinemann, M. Thorogood, K.D. MacRae.
Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
Bmj, 312 (1996), pp. 83-88
[5.]
G. Tans, J. Curvers, S. Middeldorp, M.C. Thomassen, J.C. Meijers, M.H. Prins, et al.
A randomized cross-over study on the effects of levonorgestrel-and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Thromb Haemost, 84 (2000), pp. 15-21
[6.]
S. Middeldorp, J.C. Meijers, A.E. Van den Ende, A. Van Enk, B.N. Bouma, G. Tans, et al.
Effects on coagulation of levonorgestrel-and desogestrel-containing low dose oral contraceptives: a cross-over study.
Thromb Haemost, 84 (2000), pp. 4-8
[7.]
J. Rosing, G. Tans, G.A. Nicolaes, M.C. Thomanssen, R. Van der Oerle, P.M. Van der Ploeg.
Oral contraceptives and venous trombosis: different sensitivies to activated protein C in women using second-and third generation oral contraceptives.
Br J Haematol, 97 (1997), pp. 233-238
[8.]
R.N. Prasad, S.C. Koh, O.A. Viegas, S.S. Ratnam.
Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
Clin Appl Thromb Hemost, 5 (1999), pp. 60-70
[9.]
S.F. De Bruijn, J. Stam, J.P. Vandenbroucke.
Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group.
[10.]
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.
Lancet, 346 (1995), pp. 1575-1582
[11.]
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease.
Lancet, 346 (1995), pp. 1582-1588
[12.]
Agencia Española del Medicamento.
Comunicación sobre riesgos de medicamentos.
Riesgo de tromboembolismo venoso asociado a la utilización de anticonceptivos orales de tercera generación 2001, Agencia Española del Medicamento, (2001),
[13.]
J.M. Kemmeren, A. Algra, D.E. Grobbee.
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.
Bmj, 323 (2001), pp. 131-134
[14.]
J.O. Drife.
The third generation pill controversy (continued).
Bmj, 323 (2001), pp. 119-120
[15.]
R. S´nchez, O. Martinez.
Guía pr´ctica en anticoncepción oral basada en la evidencia.
Emisa, (2003),
[16.]
J. Rosing, S. Middeldorp, J. Curvers, M. Christela, L.G. Thomassen, G.A. Nicolaes, et al.
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Lancet, 354 (1999), pp. 2036-2040
Copyright © 2004. Sociedad Española de Ginecología y Obstetricia
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos